- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07465289
Um Estudo para Avaliar a Segurança e Eficácia a Longo Prazo do Rozanolixizumab em Participantes Adultos com Miastenia Gravis Ocular (MyVisionXT)
Um Estudo de Extensão de Fase 3, Aberto, para Avaliar a Segurança e Eficácia a Longo Prazo do Rozanolixizumab em Participantes Adultos com Miastenia Gravis Ocular
The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: UCB Cares
- Número de telefone: +18445992273
- E-mail: ucbcares@ucb.com
Estude backup de contato
- Nome: UCB Cares
- Número de telefone: 00184459922733 (UCB)
- E-mail: ucbcares@ucb.com
Locais de estudo
-
-
-
Beijing, China
- Recrutamento
- Mg0039 31901
-
Beijing, China
- Recrutamento
- Mg0039 31912
-
Chongqing, China
- Recrutamento
- Mg0039 31908
-
Nanchang, China
- Recrutamento
- Mg0039 31907
-
Suzhou, China
- Recrutamento
- Mg0039 31902
-
-
-
-
-
Barcelona, Espanha
- Recrutamento
- Mg0039 20604
-
Madrid, Espanha
- Recrutamento
- Mg0039 20611
-
Murcia, Espanha
- Recrutamento
- Mg0039 20602
-
Málaga, Espanha
- Recrutamento
- Mg0039 20606
-
-
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85251
- Recrutamento
- Mg0039 10104
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Recrutamento
- Mg0039 10103
-
-
-
-
-
Nice, França
- Recrutamento
- Mg0039 20301
-
-
-
-
-
Sarajishvili, Geórgia
- Recrutamento
- Mg0039 21403
-
Tbilisi, Geórgia
- Recrutamento
- Mg0039 21402
-
-
-
-
-
Kobe, Japão
- Recrutamento
- Mg0039 31802
-
Minatoku, Japão
- Recrutamento
- Mg0039 31804
-
Sendai, Japão
- Recrutamento
- Mg0039 31805
-
-
-
-
-
Lublin, Polônia
- Recrutamento
- Mg0039 21206
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Participant must be a minimum of 18 years of age inclusive at the time of signing the informed consent form (ICF)
-
Participant must have received at least 1 dose of investigational medicinal product (IMP) (rozanolixizumab or placebo) in MG0038
-
Participant for whom the investigator considers a favorable benefit/risk for participation
-
Participant who, alone or with assistance of the caregiver, is considered reliable and capable of adhering to the protocol visit schedule or medication intake according to the judgement of the investigator
-
Male or female
-
A female participant is eligible to participate if she is not, not breastfeeding (including pumping breastmilk to feed a child), and at least 1 of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
- A WOCBP who agrees to follow the contraceptive guidance for the entire study period
-
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
Exclusion Criteria:
- Participant meets any of the withdrawal criteria defined in MG0038
- Participant has a clinically relevant active infection (resulting in hospitalization or requiring intravenous (IV) antibiotic treatment) within 6 weeks before study entry.
- Participant intends to have a live vaccination during the study or within 8 weeks following the final dose of rozanolixizumab
- Participant has been administered with the prohibited immunosuppressive medications, biologics, or other therapies
- Participant has planned use of prohibited medications
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Rozanolixizumab
The study is composed of Extended Observation Period(s) and Symptom-driven Cycle(s). Based on their clinical need for treatment, study participants will be able to start the study with either an Extended Observation Period or a Symptom-driven Cycle. A Symptom-driven Cycle will be initiated based on disease worsening and participants will receive rozanolixizumab based on investigator's medical judgement. |
Rozanolixizumab will be administered by subcutaneous infusion.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAEs)
Prazo: Up to 2 years
|
Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment. |
Up to 2 years
|
|
Incidence of treatment-emergent serious adverse events (TESAEs)
Prazo: Up to 2 years
|
An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed:
|
Up to 2 years
|
|
Incidence of TEAEs leading to permanent withdrawal of study treatment
Prazo: Up to 2 years
|
Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment. This measure considers any TEAE leading to permanent withdrawal from study. |
Up to 2 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome part)
Prazo: At Day 43 (of the first 3 Symptom-driven Cycles)
|
MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week". |
At Day 43 (of the first 3 Symptom-driven Cycles)
|
|
Change from Baseline at Day 43 in Myasthenia Gravis Activities of Daily Living (MG-ADL) ocular score
Prazo: At Day 43 (of the first 3 Symptom-driven Cycles)
|
The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability. The two ocular items will be summed for the ocular score, ranging from 0 to 6. |
At Day 43 (of the first 3 Symptom-driven Cycles)
|
|
Change from Baseline at Day 43 in Myasthenia Gravis Symptoms Patient-Reported Outcome (MGSPRO) ocular muscle weakness scale score
Prazo: At Day 43 (of the first 3 Symptom-driven Cycles)
|
The MG symptoms PRO instrument consisted of 42 items across 5 scales: ocular muscle weakness (items 1-5); bulbar muscle weakness (items 6-15); respiratory muscle weakness (items 16-18); physical fatigue (items 19-33) and muscle weakness fatigability (items 34-42). Only the ocular muscle weakness scale will be used in this study. Ocular symptom severity is assessed over the past 7 days using a 4-point verbal rating scale (none, mild, moderate, severe) |
At Day 43 (of the first 3 Symptom-driven Cycles)
|
|
Change from Baseline at Day 43 in Myasthenia Gravis Quality of Life 15-item Scale (revised version) (MG-QoL15r) total score
Prazo: At Day 43 (of the first 3 Symptom-driven Cycles)
|
The MG-QoL15r is a 15-item PRO measure that is designed to assess aspects of health-related quality of life related to MG. The recall period that will be used is "past 7 days". Each item has 3 response options (0-2) and the total score ranges from 0 to 30, with higher scores indicating more severe impact on health-related QoL (HRQOL). |
At Day 43 (of the first 3 Symptom-driven Cycles)
|
|
Study participant who generalizes to Myasthenia Gravis Foundation of America (MGFA) class ≥2 over time
Prazo: Up to 2 years
|
MGFA Clinical Classification is a 5-stage classification (I to V), with a higher class indicating more severe disease. |
Up to 2 years
|
|
Change from Baseline in MGII total and generalized score over time
Prazo: Up to 2 years
|
MGII is a measure of disease severity based on the signs and symptoms of MG patients. The MGII has 22 patient-reported items and 6 examination items and scores are presented as a sum of all items for a total score but also as an ocular and generalized sub-score. The scoring range is 0 to 84, 0-23 for the ocular score, and 0-61 for the generalized score, where higher scores are indicative of more severe symptoms. The recall period is "the past week". |
Up to 2 years
|
|
Change from Baseline in MG-ADL total score over time
Prazo: Up to 2 years
|
The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability. The two ocular items will be summed for the ocular score, ranging from 0 to 6. |
Up to 2 years
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Neoplasias por local
- Neoplasias
- Doenças Neuromusculares
- Doenças autoimunes
- Doenças do sistema imunológico
- Doenças Autoimunes do Sistema Nervoso
- Doenças Neurodegenerativas
- Síndromes Paraneoplásicas do Sistema Nervoso
- Neoplasias do Sistema Nervoso
- Síndromes Paraneoplásicas
- Doenças da Junção Neuromuscular
- Miastenia grave
- Rozanolixizumab
Outros números de identificação do estudo
- MG0039
- 2025-524757-14-00 (Ctis)
- U1111-1334-3218 (Outro identificador: Universal Trial Number)
- CTR20262521 (Identificador de registro: ChinaDrugTrials.org.cn)
- 2025 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Prazo de Compartilhamento de IPD
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Critérios de acesso de compartilhamento IPD
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .